Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor

Each study is a prospective, multi-center, non-randomized, open-label, out patient clinical
trial which will include up to 240 subjects per study. Subjects will be male and female, age
40-80 years, with approximately 20 sites per study.

Subjects will participate in 5 study visits over the course of the study period. The
screening visit will include an assessment of eligibility. The second visit will be the
collection of the community neurologist's diagnostic assessment. The third visit, during
which all subjects receive a single intravenous (IV) injection of 123I-ALTROPANE® and single
photon emission computed tomography (SPECT) imaging, will include appropriate safety
assessments before and after dosing. The fourth visit, to occur 24 to 72 hours after SPECT
imaging, will include follow up safety assessments as well as the first Movement Disorder
Specialist's (MDS) evaluation. The fifth visit, to occur 6 months (±7 days) after SPECT
imaging, will include follow-up safety assessments as well as the MDS reevaluation and truth
standard diagnosis. The subject's participation in the study will be up to 7 months.

Inclusion Criteria:

1. Subjects must provide written informed consent prior to the initiation of any study
related procedures;

2. Age 40 to 80 years;

3. Subjects must have had upper extremity tremor for < 3 years duration.

Exclusion Criteria:

1. Any clinically significant acute or unstable physical or psychological illness based
on medical history or physical examination at Visit 1, as determined by the PI;

2. Any unexpected clinically significant abnormal laboratory or electrocardiogram (ECG)
results obtained at Visit 1 and as determined by the PI;

3. Any history or drug, narcotic, or alcohol abuse within 2 years before the date of
informed consent, as defined by the Diagnostic and Statistical Manual of the American
Psychiatric Association, Fourth Edition, revised DSM-IVR, American Psychiatric
Association, 1994;

4. Positive drug screen for opiates, cocaine or amphetamines at Visit 1;

5. Positive pregnancy test at Visit 1 and/or Visit 3;

6. Participation in an investigational drug or device clinical trial within 30 days
prior to the date of informed consent;

7. Previous participation in any 123I-ALTROPANE® trial;

8. Any exposure to radiopharmaceuticals within 30 days prior to the date of informed
consent;

9. Breast-feeding;

10. Inability to lie supine for 1 hour;

11. Any thyroid disease other than treated hypothyroidism;

12. Known sensitivity or allergy to iodine or iodine containing products;

13. Treatment within the 4 weeks before the date of the informed consent with buproprion,
methylphenidate or amphetamine;

14. Any treatment with anti-Parkinson's drugs within 4 weeks before the date of informed
consent.

Subject eligibility based on exclusion criteria 1, 2, 3, 4, and 20 will be confirmed at
Visit 3 prior to dosing.